• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PRDS

    Pardes Biosciences Inc.

    Subscribe to $PRDS
    $PRDS
    Medicinal Chemicals and Botanical Products
    Health Care

    Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: https://www.pardesbio.com

    Recent Analyst Ratings for Pardes Biosciences Inc.

    DatePrice TargetRatingAnalyst
    7/18/2023Mkt Outperform → Mkt Perform
    JMP Securities
    3/15/2022Outperform
    SVB Leerink
    1/18/2022$25.00Buy
    Jefferies
    See more ratings